Home/Filings/8-K/0001493152-25-029157
8-K//Current report

Brand Engagement Network Inc. 8-K

Accession 0001493152-25-029157

$BNAICIK 0001838163operating

Filed

Dec 28, 7:00 PM ET

Accepted

Dec 29, 6:08 AM ET

Size

222.9 KB

Accession

0001493152-25-029157

Research Summary

AI-generated summary of this filing

Updated

Brand Engagement Network Inc. Announces AI Development Deal for Pharma

What Happened
Brand Engagement Network, Inc. (BEN) filed an 8-K reporting that on December 19, 2025 it entered a Vendor Services Project Agreement with a leading global advertising and communications agency (unit of a major advertising holding company) under a purchase order dated the same day. The Agreement calls for BEN to develop a custom AI engagement communication solution supporting an established prescription pharmaceutical product for a top‑10 global pharmaceutical client (both client identities remain confidential). BEN expects to recognize $250,000 in revenue in Q4 2025 for development services under two Statements of Work, subject to performance and client acceptance. Monthly recurring license fees separate from development are anticipated to begin in Q1 2026, subject to final implementation and deployment.

Key Details

  • Agreement date: December 19, 2025 (purchase order received same day).
  • Expected near‑term revenue: $250,000 to be recognized in Q4 2025 for development services (subject to performance and acceptance).
  • Commercial outlook: Monthly recurring license fees are anticipated to commence in Q1 2026 if implementation and deployment are completed.
  • Scope: Development of a custom AI engagement communication solution for an established prescription product; identities of agency and pharma client remain confidential pending release.

Why It Matters
This deal signals potential near-term revenue and the possibility of recurring license income beginning in early 2026. For investors, the $250,000 expected in Q4 2025 is a measurable near-term contribution to revenue, while the anticipated recurring fees could provide ongoing revenue if implementation and client acceptance proceed. The engagement with a major global agency and a top‑10 pharma client—though currently confidential—may also represent validation of BEN’s AI capabilities and could support future business opportunities.